Anne E. Beenken
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Blinatumomab in refractory SLE-associated immune thrombocytopenia.
Journal: Annals of the rheumatic diseases
Published: July 01, 2026
Increased Type I Interferon Activity with Concurrent Plasmablast Expansion Identifies Systemic Lupus Erythematosus Patients with Poor Outcomes.
Journal: International journal of molecular sciences
Published: February 28, 2026
Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series.
Journal: Annals of the rheumatic diseases
Published: January 19, 2026
Comment on: Glucocorticoid discontinuation in systemic lupus erythematosus: a single-centre study.
Journal: Rheumatology advances in practice
Published: July 14, 2025
Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial.
Journal: Nature communications
Published: July 11, 2025
Confounding by indication in observational studies investigating glucocorticoid-associated adverse events in patients with rheumatoid arthritis: a systematic literature review including an assessment of E-values.
Journal: Annals of the rheumatic diseases
Published: May 30, 2025
IgG4-related disease has a specific intestinal microbiota signature.
Journal: EBioMedicine
Published: April 27, 2025
Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation.
Journal: Annals of the rheumatic diseases
Published: November 25, 2024
B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus.
Journal: International journal of molecular sciences
Published: August 30, 2024
Showing 1-9 of 9
Last Updated: 09/26/2026